Contract from the US Department of Defense and market approval for Chikungunya vaccine in the UK!
The growing desire to travel could drive demand for prophylactic vaccinations against infectious diseases!
Reading Time: 1 minute
The biopharmaceutical company Valneva SE has faced some significant setbacks in the past, particularly related to its research on a Covid-19 vaccine. However, the news outlook is starting to improve. Since the end of January 2025, two notable impulses for rising prices have already emerged. First, a new contract worth $32.8 million has been signed with the US Department of Defense (DoD) for the delivery of the IXIARO vaccine against Japanese Encephalitis (JE). Second, the British Medicines and Healthcare products Regulatory Agency (MHRA) has granted...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
